(Q35643948)

9 August 2017

1 reference

title

Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent (English)

1 reference

9 August 2017

1 reference

0 references

1

Robert B Belshe

1 reference

9 August 2017

Paul M Mendelman

2

1 reference

9 August 2017

publication date

1 November 2003

1 reference

Immunology and Allergy Clinics of North America

9 August 2017

published in

1 reference

9 August 2017

volume

23

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

745-767

1 reference

Prevention of otitis media in children with live attenuated influenza vaccine given intranasally

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Genetics of cold-adapted B/Ann Arbor/1/66 influenza virus reassortants: the acidic polymerase (PA) protein gene confers temperature sensitivity and attenuated virulence

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Comparative studies of wild-type and cold-mutant (temperature-sensitive) influenza viruses: nonrandom reassortment of genes during preparation of live virus vaccine candidates by recombination at 25 degrees between recent H3N2 and H1N1 epidemic stra

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Evaluation of a cold-recombinant influenza virus vaccine in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Determinants of immunity to influenza infection in man

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Influenza at Christ's Hospital: March, 1974.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Cold-recombinant influenza A/California/10/78 (H1N1) virus vaccine (CR-37) in seronegative children: infectivity and efficacy against investigational challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Pilot Studies on Recombinant Cold-Adapted Live Type A and B Influenza Virus Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Studies with a cold-recombinant A/Victoria/3/75 (H3N2) virus. II. Evaluation in adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Studies in man with cold-recombinant influenza virus (H1N1) live vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Characterization and clinical evaluation of live influenza A vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and the cold-adapted A/Ann Arbor/6/60 (H2N2) strains

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

Cold-adapted recombinant influenza A virus vaccines in seronegative young children

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2803%2900098-5

7 January 2021

10.1016/S0889-8561(03)00098-5

Identifiers

DOI

1 reference

9 August 2017

1 reference